Skip to main content
Top
Published in: Infection 6/2011

01-12-2011 | Clinical and Epidemiological Study

Increase of patients co-colonised or co-infected with methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium or extended-spectrum β-lactamase-producing Enterobacteriaceae

Authors: E. Meyer, R. Ziegler, F. Mattner, F. Schwab, P. Gastmeier, M. Martin

Published in: Infection | Issue 6/2011

Login to get access

Abstract

Purpose

To determine the incidence of patients co-colonised or co-infected with methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus faecium or extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae in four German tertiary care hospitals.

Methods

This study was conducted at four tertiary care hospitals (all with >1,000 beds) in different geographic regions in Germany (Berlin in the east, Luebeck in the north, Freiburg in the southwest and Nuernberg in the southeast). Routine surveillance data on MRSA, vancomycin-resistant enterococci (VRE) and ESBL-producing bacteria were analysed from 2007 to 2009. Co-colonisation or co-infection was defined as a patient having positive cultures for at least two of the following resistant pathogens: MRSA, VRE faecium or different species of ESBL-producing Enterobacteriaceae within one calendar year.

Results

A total of 896,822 patients were analysed, of which 10,066 patients harboured MRSA, VRE faecium and/or ESBL-producing Enterobacteriaceae, and 542 patients co-harboured at least two of those resistant pathogens. In 2009, 7.6% of the MRSA patients, 13.7% of the VRE faecium patients and even 16.1% of the ESBL-producing Enterobacteriaceae patients were co-colonised or co-infected. The incidence of patients with co-infection or co-colonisation increased steadily from 5 (2007) to 7 per 10,000 patients (2009).

Conclusions

Patients harbouring ESBL-producing Enterobacteriaceae or VRE faecium had a higher risk of being co-colonised or co-infected compared to what was to be extrapolated from their overall incidence. This might be linked to their gastrointestinal reservoir and impracticality to decolonise the gut of resistant VRE and ESBL-producing Enterobacteriaceae.
Literature
1.
go back to reference Han SH, Chin BS, Lee HS, Jeong SJ, Choi HK, Kim CK, Kim CO, Yong D, Choi JY, Song YG, Lee K, Kim JM. Recovery of both vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus from culture of a single clinical specimen from colonized or infected patients. Infect Control Hosp Epidemiol. 2009;30:130–8.PubMedCrossRef Han SH, Chin BS, Lee HS, Jeong SJ, Choi HK, Kim CK, Kim CO, Yong D, Choi JY, Song YG, Lee K, Kim JM. Recovery of both vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus from culture of a single clinical specimen from colonized or infected patients. Infect Control Hosp Epidemiol. 2009;30:130–8.PubMedCrossRef
2.
go back to reference Warren DK, Nitin A, Hill C, Fraser VJ, Kollef MH. Occurrence of co-colonization or co-infection with vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus in a medical intensive care unit. Infect Control Hosp Epidemiol. 2004;25:99–104.PubMedCrossRef Warren DK, Nitin A, Hill C, Fraser VJ, Kollef MH. Occurrence of co-colonization or co-infection with vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus in a medical intensive care unit. Infect Control Hosp Epidemiol. 2004;25:99–104.PubMedCrossRef
3.
go back to reference Furuno JP, Perencevich EN, Johnson JA, Wright MO, McGregor JC, Morris JG Jr, Strauss SM, Roghman MC, Nemoy LL, Standiford HC, Hebden JN, Harris AD. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci co-colonization. Emerg Infect Dis. 2005;11:1539–44.PubMed Furuno JP, Perencevich EN, Johnson JA, Wright MO, McGregor JC, Morris JG Jr, Strauss SM, Roghman MC, Nemoy LL, Standiford HC, Hebden JN, Harris AD. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci co-colonization. Emerg Infect Dis. 2005;11:1539–44.PubMed
4.
go back to reference Ho PL. Carriage of methicillin-resistant Staphylococcus aureus, ceftazidime-resistant gram-negative bacilli, and vancomycin-resistant enterococci before and after intensive care unit admission. Crit Care Med. 2003;31:1175–82.PubMedCrossRef Ho PL. Carriage of methicillin-resistant Staphylococcus aureus, ceftazidime-resistant gram-negative bacilli, and vancomycin-resistant enterococci before and after intensive care unit admission. Crit Care Med. 2003;31:1175–82.PubMedCrossRef
5.
go back to reference Reyes K, Malik R, Moore C, Donabedian S, Perri M, Johnson L, Zervos M. Evaluation of risk factors for coinfection or cocolonization with vancomycin-resistant enterococcus and methicillin-resistant Staphylococcus aureus. J Clin Microbiol. 2010;48:628–30.PubMedCrossRef Reyes K, Malik R, Moore C, Donabedian S, Perri M, Johnson L, Zervos M. Evaluation of risk factors for coinfection or cocolonization with vancomycin-resistant enterococcus and methicillin-resistant Staphylococcus aureus. J Clin Microbiol. 2010;48:628–30.PubMedCrossRef
6.
go back to reference Wang Z, Cao B, Liu YM, Gu L, Wang C. Investigation of the prevalence of patients co-colonized or infected with methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci in China: a hospital-based study. Chin Med J. 2009;122:1283–8.PubMed Wang Z, Cao B, Liu YM, Gu L, Wang C. Investigation of the prevalence of patients co-colonized or infected with methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci in China: a hospital-based study. Chin Med J. 2009;122:1283–8.PubMed
7.
go back to reference Franchi D, Climo MW, Wong AH, Edmond MB, Wenzel RP. Seeking vancomycin resistant Staphylococcus aureus among patients with vancomycin-resistant enterococci. Clin Infect Dis. 1999;29:1566–8.PubMedCrossRef Franchi D, Climo MW, Wong AH, Edmond MB, Wenzel RP. Seeking vancomycin resistant Staphylococcus aureus among patients with vancomycin-resistant enterococci. Clin Infect Dis. 1999;29:1566–8.PubMedCrossRef
8.
go back to reference Harris AD, Nemoy L, Johnson JA, Martin-Carnahan A, Smith DL, Standiford H, Perencevich EN. Co-carriage rates of vancomycin-resistant Enterococcus and extended-spectrum beta-lactamase-producing bacteria among a cohort of intensive care unit patients: implications for an active surveillance program. Infect Control Hosp Epidemiol. 2004;25:105–8.PubMedCrossRef Harris AD, Nemoy L, Johnson JA, Martin-Carnahan A, Smith DL, Standiford H, Perencevich EN. Co-carriage rates of vancomycin-resistant Enterococcus and extended-spectrum beta-lactamase-producing bacteria among a cohort of intensive care unit patients: implications for an active surveillance program. Infect Control Hosp Epidemiol. 2004;25:105–8.PubMedCrossRef
9.
go back to reference Chang S, Sievert DM, Hageman JC, Boulton ML, Tenover FC, Downes FP, Shah S, Rudrik JT, Pupp GR, Brown WJ, Cardo D, Fridkin SK. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med. 2003;348:1342–7.PubMedCrossRef Chang S, Sievert DM, Hageman JC, Boulton ML, Tenover FC, Downes FP, Shah S, Rudrik JT, Pupp GR, Brown WJ, Cardo D, Fridkin SK. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med. 2003;348:1342–7.PubMedCrossRef
10.
go back to reference Meyer E, Serr A, Schneider C, Utzolino S, Kern WV, Scholz R, Dettenkofer M. Should we screen patients for extended-spectrum beta-lactamase-producing enterobacteriaceae in intensive care units? Infect Control Hosp Epidemiol. 2009;30:103–5.PubMedCrossRef Meyer E, Serr A, Schneider C, Utzolino S, Kern WV, Scholz R, Dettenkofer M. Should we screen patients for extended-spectrum beta-lactamase-producing enterobacteriaceae in intensive care units? Infect Control Hosp Epidemiol. 2009;30:103–5.PubMedCrossRef
Metadata
Title
Increase of patients co-colonised or co-infected with methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium or extended-spectrum β-lactamase-producing Enterobacteriaceae
Authors
E. Meyer
R. Ziegler
F. Mattner
F. Schwab
P. Gastmeier
M. Martin
Publication date
01-12-2011
Publisher
Springer-Verlag
Published in
Infection / Issue 6/2011
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-011-0154-0

Other articles of this Issue 6/2011

Infection 6/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine